NASDAQ:GBT - Global Blood Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $41.40 -0.65 (-1.55 %) (As of 07/19/2018 03:12 PM ET)Previous Close$41.85Today's Range$40.35 - $41.8552-Week Range$24.02 - $68.05Volume41,569 shsAverage Volume2.14 million shsMarket Capitalization$2.13 billionP/E Ratio-14.82Dividend YieldN/ABeta4.42 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California. Receive GBT News and Ratings via Email Sign-up to receive the latest news and ratings for GBT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:GBT CUSIPN/A Webwww.gbt.com Phone650-741-7700 Debt Debt-to-Equity RatioN/A Current Ratio23.12 Quick Ratio23.12 Price-To-Earnings Trailing P/E Ratio-14.82 Forward P/E Ratio-11.50 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$6.93 per share Price / Book5.97 Profitability EPS (Most Recent Fiscal Year)($2.76) Net Income$-117,020,000.00 Net MarginsN/A Return on Equity-38.74% Return on Assets-35.69% Miscellaneous Employees147 Outstanding Shares51,830,000Market Cap$2,130.04 Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions What is Global Blood Therapeutics' stock symbol? Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT." How were Global Blood Therapeutics' earnings last quarter? Global Blood Therapeutics Inc (NASDAQ:GBT) released its quarterly earnings results on Monday, May, 7th. The company reported ($0.87) EPS for the quarter, beating analysts' consensus estimates of ($0.91) by $0.04. During the same period in the prior year, the business posted ($0.60) earnings per share. View Global Blood Therapeutics' Earnings History. When is Global Blood Therapeutics' next earnings date? Global Blood Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Global Blood Therapeutics. What price target have analysts set for GBT? 13 brokers have issued 12-month price targets for Global Blood Therapeutics' stock. Their forecasts range from $46.00 to $125.00. On average, they expect Global Blood Therapeutics' share price to reach $80.8462 in the next year. This suggests a possible upside of 98.6% from the stock's current price. View Analyst Ratings for Global Blood Therapeutics. What is the consensus analysts' recommendation for Global Blood Therapeutics? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Global Blood Therapeutics stock? Here are some recent quotes from research analysts about Global Blood Therapeutics stock: 1. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and raising our 12- month price target to $96 from $69, following release of Part A data in sickle cell disease (SCD). We believe the demonstrated clinical benefit of at least 1g/dL improvement in hemoglobin in 58% of 1500mg voxelotor-treated patients, compared with 9% of placebo patients (p<0.0001), provides further support of the treatment's potential for approval. Further results from the study will be presented at a medical meeting later this year, along with an update on regulatory discussions with the FDA to seek accelerated approval. GBT shares are down 12% in pre- market trading."" (6/27/2018) 2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (5/2/2018) 3. Needham & Company LLC analysts commented, "Here we review our expectations for Part A of the HOPE trial which includes survey findings from 36 sickle cell disease (SCD) experts. We believe there is more than one path forward for voxelotor, but we think upside potential could vary significantly based on Part A findings. If reported Part A outcomes meet expectations as defined below, we think the stock could easily return to the $70 level (+60%) it was trading at in January." (4/26/2018) 4. Cowen Inc analysts commented, "GBT reported Q3 earnings last week and provided a brief summary of their progress." (11/9/2017) Who are some of Global Blood Therapeutics' key competitors? Some companies that are related to Global Blood Therapeutics include Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), FibroGen (FGEN), United Therapeutics (UTHR), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO) and Ultragenyx Pharmaceutical (RARE). Who are Global Blood Therapeutics' key executives? Global Blood Therapeutics' management team includes the folowing people: Dr. Ted W. Love, Pres, CEO & Director (Age 59)Dr. Charles J. Homcy, Founder, Advisor & Director (Age 70)Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 56)Mr. Peter Radovich, Sr. VP of Operations (Age 40)Dr. Hing Sham, Sr. VP of Research (Age 66) When did Global Blood Therapeutics IPO? (GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers. Has Global Blood Therapeutics been receiving favorable news coverage? Press coverage about GBT stock has trended positive this week, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Global Blood Therapeutics earned a news impact score of 0.25 on Accern's scale. They also gave news stories about the company an impact score of 45.70 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. Who are Global Blood Therapeutics' major shareholders? Global Blood Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Daiwa SB Investments Ltd. (0.06%), Fred Alger Management Inc. (0.06%), Essex Investment Management Co. LLC (0.05%) and Amalgamated Bank (0.01%). Company insiders that own Global Blood Therapeutics stock include Charles J Homcy, Deval L Patrick, Jung Choi, Kevin P Starr, Lesley Ann Calhoun, Perceptive Advisors Llc, Peter Radovich and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics. Which major investors are buying Global Blood Therapeutics stock? GBT stock was acquired by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Essex Investment Management Co. LLC, Daiwa SB Investments Ltd. and Amalgamated Bank. View Insider Buying and Selling for Global Blood Therapeutics. How do I buy shares of Global Blood Therapeutics? Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Global Blood Therapeutics' stock price today? One share of GBT stock can currently be purchased for approximately $40.70. How big of a company is Global Blood Therapeutics? Global Blood Therapeutics has a market capitalization of $2.13 billion. The company earns $-117,020,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Global Blood Therapeutics employs 147 workers across the globe. How can I contact Global Blood Therapeutics? Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected] MarketBeat Community Rating for Global Blood Therapeutics (NASDAQ GBT)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 306 (Vote Outperform)Underperform Votes: 162 (Vote Underperform)Total Votes: 468MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe GBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/19/2018 by MarketBeat.com StaffFeatured Article: What do investors mean by earnings per share?